Unity Biotechnology has patented a method using small molecule drugs to target senescent cells in the eye, correlating their abundance with age-related conditions. The drugs not only inhibit disease progression but also reverse pathophysiology, offering potential treatment for previously intractable ophthalmic conditions. GlobalData’s report on Unity Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Unity Biotechnology Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Unity Biotechnology, Cancer treatment biomarkers was a key innovation area identified from patents. Unity Biotechnology's grant share as of February 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Senolytic agents for treating age-related eye conditions

Source: United States Patent and Trademark Office (USPTO). Credit: Unity Biotechnology Inc

A recently granted patent (Publication Number: US11865123B2) discloses a method for promoting vascular repair in the eye of a subject in need. The method involves administering a therapeutically effective dose of a pharmaceutical composition containing a specific compound selected from a defined group. The promotion of vascular repair is aimed at reversing neovascularization and/or vaso-obliteration in the eye, addressing conditions such as diabetic retinopathy, diabetic macular edema, age-related macular degeneration, geographic atrophy, or retinopathy of prematurity.

Furthermore, the method specifies the administration of the pharmaceutical composition intravitreally, ensuring targeted delivery for optimal efficacy. This patent highlights a novel approach to addressing vascular repair in the eye, offering potential benefits for individuals suffering from various eye conditions requiring such intervention. The specific compound selected for the pharmaceutical composition plays a crucial role in promoting vascular repair, potentially opening up new avenues for treatment and management of eye-related vascular issues.

To know more about GlobalData’s detailed insights on Unity Biotechnology, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies